ENSC Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Ensysce Biosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerENSC

Market Cap4.2M

Cash RunwayRunway < 6 months

Next Catalyst2026-08

Public Research Snapshot

Ensysce Biosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for PF614 capsule in Postoperative Pain, Acute (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Chief Commercial Officer	n/a	n/a	Phase 2	Public pipeline row
Chief Development Officer	n/a	n/a	IND-enabling	Public pipeline row
PF614	Acute Pain	n/a	Phase 2	Public pipeline row
PF614 capsule	Postoperative Pain, Acute	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-08	PF614 capsule	Low
		Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06629402	Phase 2	COMPLETED	16	2023-11-14
NCT06602271	Phase 3	RECRUITING	320	2026-08

Scientific Context

catalyst_type | Data Readout
literature_publication | Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
literature_publication | Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.
literature_publication | In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.
literature_publication | Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?

Want the full ENSC research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.